These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 23086587

  • 1. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.
    De Salas-Cansado M, Álvarez E, Olivares JM, Carrasco JL, Ferro MB, Rejas J.
    Soc Psychiatry Psychiatr Epidemiol; 2013 Jun; 48(6):985-96. PubMed ID: 23086587
    [Abstract] [Full Text] [Related]

  • 2. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.
    De Salas-Cansado M, Olivares JM, Alvarez E, Carrasco JL, Barrueta A, Rejas J.
    Clinicoecon Outcomes Res; 2012 Jun; 4():157-68. PubMed ID: 22745564
    [Abstract] [Full Text] [Related]

  • 3. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
    de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, González-Gómez FJ, Ruiz L, Rejas J.
    Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
    [Abstract] [Full Text] [Related]

  • 4. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.
    de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, Rejas J.
    Pain Med; 2012 May; 13(5):699-710. PubMed ID: 22594706
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.
    Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G.
    Eur J Health Econ; 2010 Feb; 11(1):35-44. PubMed ID: 19506926
    [Abstract] [Full Text] [Related]

  • 6. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain.
    Carrasco JL, Álvarez E, Olivares JM, Rejas J.
    Actas Esp Psiquiatr; 2013 Feb; 41(3):164-74. PubMed ID: 23803800
    [Abstract] [Full Text] [Related]

  • 7. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial.
    Luciano JV, D'Amico F, Cerdà-Lafont M, Peñarrubia-María MT, Knapp M, Cuesta-Vargas AI, Serrano-Blanco A, García-Campayo J.
    Arthritis Res Ther; 2014 Oct 01; 16(5):451. PubMed ID: 25270426
    [Abstract] [Full Text] [Related]

  • 8. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors.
    Álvarez E, Olivares JM, Carrasco JL, López-Gómez V, Rejas J.
    Ann Gen Psychiatry; 2015 Oct 01; 14(1):2. PubMed ID: 25632294
    [Abstract] [Full Text] [Related]

  • 9. A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.
    Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.
    BMC Neurol; 2011 Jan 20; 11():7. PubMed ID: 21251268
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
    Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP.
    Clin Drug Investig; 2008 Jan 20; 28(9):583-601. PubMed ID: 18666805
    [Abstract] [Full Text] [Related]

  • 11. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective.
    Darbà J, Kaskens L, Pérez C, Álvarez E, Navarro-Artieda R, Sicras-Mainar A.
    Adv Ther; 2014 Jan 20; 31(1):1-29. PubMed ID: 24390901
    [Abstract] [Full Text] [Related]

  • 12. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
    Ritchie M, Liedgens H, Nuijten M.
    Clin Drug Investig; 2010 Jan 20; 30(2):71-87. PubMed ID: 20067326
    [Abstract] [Full Text] [Related]

  • 13. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
    Chevalier P, Lamotte M, Van Campenhout H, Eyckerman R, Annemans L.
    J Med Econ; 2013 Jan 20; 16(5):596-605. PubMed ID: 23409950
    [Abstract] [Full Text] [Related]

  • 14. The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.
    Rovira J, Albarracin G, Salvador L, Rejas J, Sánchez-Iriso E, Cabasés JM.
    Community Ment Health J; 2012 Jun 20; 48(3):372-83. PubMed ID: 22484993
    [Abstract] [Full Text] [Related]

  • 15. [Analysis of the cost-effectiveness of treatment for refractory partial epilepsy: a simulation model for pregabalin and levetiracetam].
    Díaz S, Argumosa A, Horga de la Parte JF, Vera-Llonch M, Dukes E, Rejas-Gutiérrez J.
    Rev Neurol; 2012 Jun 20; 45(8):460-7. PubMed ID: 17948211
    [Abstract] [Full Text] [Related]

  • 16. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain.
    Gordon J, Lister S, Prettyjohns M, McEwan P, Tetlow A, Gabriel Z.
    J Med Econ; 2012 Jun 20; 15(2):207-18. PubMed ID: 22017236
    [Abstract] [Full Text] [Related]

  • 17. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
    Navarro A, Saldaña MT, Pérez C, Masramón X, Rejas J.
    Pain Pract; 2012 Jun 20; 12(5):382-93. PubMed ID: 22004531
    [Abstract] [Full Text] [Related]

  • 18. Psychotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Health Technology Assessment.
    Health Quality Ontario .
    Ont Health Technol Assess Ser; 2017 Jun 20; 17(15):1-167. PubMed ID: 29213344
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
    Choy E, Richards S, Bowrin K, Watson P, Lloyd A, Sadosky A, Zlateva G.
    Curr Med Res Opin; 2010 Apr 20; 26(4):965-75. PubMed ID: 20178405
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
    Rodríguez MJ, Díaz S, Vera-Llonch M, Dukes E, Rejas J.
    Curr Med Res Opin; 2007 Oct 20; 23(10):2585-96. PubMed ID: 17875242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.